Amid the successful development of specific pharmacological inhibitors of RIPK2 kinase [226,227], and synthetic NOD2 activators such as Murabutide [228] that can be used as postbiotics, clarification concerning the function of these proteins in obesity could open new possibilities for treating the MetS in the long term. This evidence concerns the gene NOD2 and obesity disorder.